Skip to content
2000
Volume 27, Issue 39
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Lurasidone is a novel azapirone derivative and atypical antipsychotic agent with a high binding affinity for dopaminergic (D), serotoninergic (5-HT), and 5-HT receptors (antagonist), a moderate affinity for 5- HT receptors (partial agonist), and no appreciable affinity for histaminergic (H) and muscarinic (M) receptors. It was recently included by the European Medication Agency among the in-label pharmacological treatments for children and adolescents affected by early onset schizophrenia. As a dopamine and serotonin antagonist, lurasidone acted on a variety of receptors and showed its efficacy both as an antipsychotic and an activating compound. Administered with food or within 30 minutes from a meal, it presents sufficient bioavailability and does not interact with most of the other drugs during metabolism. With little effects on hormones and weight gain, potential procognitive profile due to its 5-HT antagonism, and reduced extrapyramidal side effects, lurasidone could be a good choice in terms of both effectiveness and tolerability, particularly for patients headed towards a long-term treatment. This article aims to summarize the available scientific evidence from the literature on the use of lurasidone in children and adolescents and to provide recommendations for clinical management and future research.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612827666210804110853
2021-11-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612827666210804110853
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test